Despite aortic stenosis (AS) relief, patients undergoing transcatheter aortic valve implantation (TAVI) are at increased risk of developing heart failure (HF) within first months of intervention. Sodium–glucose co-transporter 2 (SGLT-2) inhibitors have been shown to reduce the risk of HF hospitalization in individuals with diabetes mellitus, reduced left ventricular ejection fraction and chronic kidney disease. However, the effect of SGLT-2 inhibitors on outcomes after TAVI is unknown. The Dapagliflozin after Transcatheter Aortic Valve Implantation (DapaTAVI) trial is designed to assess the clinical benefit and safety of the SGLT-2 inhibitor dapagliflozin in patients undergoing TAVI.

中文翻译：

---

经导管主动脉瓣植入 (DapaTAVI) 随机试验后 Dapagliflozin 的原理和设计

尽管主动脉瓣狭窄 (AS) 得到缓解，但接受经导管主动脉瓣植入 (TAVI) 的患者在干预的最初几个月内发生心力衰竭 (HF) 的风险增加。钠-葡萄糖协同转运蛋白 2 (SGLT-2) 抑制剂已被证明可降低糖尿病患者因心衰住院、左心室射血分数降低和慢性肾病患者住院的风险。然而，SGLT-2 抑制剂对 TAVI 后结果的影响尚不清楚。经导管主动脉瓣植入术后达格列净 (DapaTAVI) 试验旨在评估 SGLT-2 抑制剂达格列净在接受 TAVI 的患者中的临床益处和安全性。